Procter & Gamble Balans Gezondheid
Financiële gezondheid criteriumcontroles 3/6
Procter & Gamble heeft een totaal eigen vermogen van $54.3B en een totale schuld van $34.1B, wat de schuld-eigenvermogensverhouding op 62.9% brengt. De totale activa en totale passiva bedragen respectievelijk $126.5B en $72.2B. De EBIT Procter & Gamble is $21.6B waardoor de rentedekking 48.3 is. Het heeft contanten en kortetermijnbeleggingen van $9.9B.
Belangrijke informatie
62.86%
Verhouding schuld/eigen vermogen
US$34.14b
Schuld
| Rente dekkingsratio | 48.3x |
| Contant | US$9.94b |
| Aandelen | US$54.31b |
| Totaal verplichtingen | US$72.21b |
| Totaal activa | US$126.52b |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
Seeking Alpha • Sep 04
Procter & Gamble: Minimal EPS Growth On The Horizon Limits The Upside
Summary The Procter & Gamble Company remains a well-run business, but its shares are unattractive at 21.15x FY27 EPS with only 1.3% expected growth. Procter & Gamble's 2.95% dividend yield is now less compelling than risk-free Treasuries, with slowing dividend growth and limited capital appreciation prospects. Fiscal 2027 guidance calls for 1–3% organic sales growth and 1.5% core EPS growth, with significant cost headwinds and Q1 EPS expected down 5%+. I remain neutral on Procter & Gamble, requiring a >4% yield and ~15x earnings (~$105–$110/share) before considering entry; index funds and Treasuries offer better alternatives. Read the full article on Seeking Alpha
Narratiefupdate • Aug 08
10-K Update
Updated with the most recent annual report.Analyse-artikel • Aug 02
Analysts Have Made A Financial Statement On The Procter & Gamble Company's (NYSE:PG) Full-Year Report
Last week saw the newest yearly earnings release from The Procter & Gamble Company ( NYSE:PG ), an important milestone...Analyse-artikel • Jun 21
Procter & Gamble (PG) Stock Could Be 19.5% Undervalued After Broad Based Growth
Procter & Gamble (PG) is back in the spotlight after reporting broad-based growth across core brands like Tide, Pampers, and Gillette, along with fresh marketing moves and continued dividend and buyback activity. See our latest analysis for Procter & Gamble. Despite the fresh product launches and media partnerships, Procter & Gamble’s recent share price return has been steady rather than dramatic, with a 30-day share price return of 4.11% and a 90-day share price return of 4.44%, while the...
Narratiefupdate • Jun 16
PG: Cost Productivity And AI Investments Will Support Future Shareholder Returns
Analysts have slightly reduced their price target on Procter & Gamble to about $163.43 from about $163.77, reflecting small adjustments to revenue growth expectations, profit margin assumptions and the projected future P/E multiple. What's in the News P&G raised its quarterly dividend by 3% to US$1.0885 per share, marking the 70th consecutive annual increase, and plans to return about US$15b to shareholders in fiscal 2026 through roughly US$10b in dividends and US$5b in share repurchases.Narratiefupdate • Jun 01
PG: Cost Productivity And Portfolio Strength Will Support Future Shareholder Returns
Analysts have slightly reduced their price target on Procter & Gamble to $163.77 from $164.09, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What's in the News P&G reported fiscal Q3 2026 net sales of US$21.24b with 3% organic sales growth and core EPS of US$1.59, ahead of analyst expectations, while maintaining full year 2026 guidance for core EPS of US$6.83 to US$7.09 and organic sales growth of 1% to 5% (source: Q3 2026 earnings reports).Narratiefupdate • May 04
PG: Brand Partnerships And Product Pipeline Will Support Future Shareholder Returns
Analysts have trimmed their Procter & Gamble price target slightly to about $164.09, reflecting modestly lower assumptions for revenue and profit margins while applying a slightly higher future P/E outlook. What's in the News P&G maintained fiscal 2026 guidance, with all-in sales growth expected in a 1% to 5% range and diluted EPS growth targeted in a 1% to 6% range versus fiscal 2025 diluted EPS of US$6.51 (Corporate guidance).Narratiefupdate • Apr 20
PG: Buybacks And Brand Partnerships Will Support Future Shareholder Returns
Analysts have slightly reduced their price target on Procter & Gamble to $164.18 from $166.95, reflecting modestly lower assumptions for revenue growth, profit margins, fair value, and future P/E multiples. What's in the News P&G revised its fiscal 2026 diluted EPS growth outlook to a range of 1% to 6%, from a prior range of 3% to 9%, citing higher non core restructuring charges, while keeping all in sales growth guidance at 1% to 5% versus the prior year (Corporate guidance).Narratiefupdate • Apr 05
PG: Share Repurchases And Premium Portfolio Refresh Will Support Future Returns
Analysts have slightly reduced their average price target for Procter & Gamble to about $167 from $168, reflecting updated views on margins and forward P/E assumptions while keeping core growth expectations largely intact. What's in the News OLAY shared new skin aging research at the 2026 American Academy of Dermatology meeting, focusing on cell adhesion as a key factor in visible aging and applying these findings to peptide based products across the Regenerist line and the new Regenerist Treatments collection (Product announcement).Narratiefupdate • Mar 22
PG: Product Refresh And Buybacks Will Support Future Earnings Resilience
Analysts kept their Procter & Gamble price target steady at $168. This reflects largely unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions.Narratiefupdate • Mar 08
PG: Brand Refresh And Buybacks Will Support Stable Earnings Outlook
Analysts have maintained their Procter & Gamble price target at $168, reflecting unchanged assumptions around revenue growth, profit margins, and future P/E. This suggests that recent research has not materially shifted their valuation view.Narratiefupdate • Feb 21
PG: Brand Activity And Buybacks Will Support Stable Margins And Outlook
Analysts have nudged their price target for Procter & Gamble higher to $168.00 from $167.45, reflecting updated assumptions for revenue growth, slightly higher profit margins and a marginally lower future P/E multiple. What's in the News Tide launched Tide evo, a 100% concentrated, waterless laundry tile with six cleaning layers and no plastic bottles, positioned to address demand for products that align with hygiene and sustainability preferences in the U.S. (Product related announcement) Head & Shoulders introduced BARE Itchy Scalp Relief Serum, aimed at providing clinically tested dandruff protection and itch relief between washes, with a nationwide U.S. launch planned for January 2026.Narratiefupdate • Feb 07
PG: Premium Brand Extensions And Stable Margins Will Support A Balanced Outlook
Analysts have nudged their price target on Procter & Gamble slightly higher to US$167.45 from about US$165.32, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E. What's in the News Old Spice launched the Spice Alchemist collection, a premium cologne-infused deodorant, body wash and body mist line positioned against high end fragrances.Narratiefupdate • Jan 25
Q2 2026 Update
Update narrative with most recent financial statements.Narratiefupdate • Jan 23
PG: Share Repurchases And Margin Pressures Will Shape A Balanced Outlook
Analysts have trimmed their price target on Procter & Gamble to US$165 from US$168, citing updated views on revenue growth, profit margins, and the future P/E multiple. What's in the News P&G updated its fiscal 2026 guidance, keeping all in sales growth for the year in a range of 1% to 5% versus the prior year, while lowering the diluted EPS growth outlook to 1% to 6% from the previous 3% to 9% range, citing higher non core restructuring charges versus fiscal 2025 diluted EPS of US$6.51 (Corporate guidance).Narratiefupdate • Jan 07
PG: Share Repurchase Will Support Future Upside With Stable Long Term Outlook
Narrative Update on Procter & Gamble The analyst price target for Procter & Gamble has shifted slightly, with updated assumptions around fair value at about $168.13, discount rate at 6.96%, revenue growth at roughly 3.12%, profit margin near 19.58%, and future P/E around 26.08x, as analysts fine tune their models on the company. What's in the News Pantene is partnering again with social media creator Alix Earle to promote the Abundant & Strong 3-Step System, including limited-edition Alix x Pantene Kits that bundle the three products with a free cosmetics bag and hairbrush for a limited time (product-related announcement).Narratiefupdate • Dec 16
PG: Share Repurchase Will Support Future Upside Amid Stable Long Term Outlook
Analysts have nudged their price target for Procter & Gamble slightly lower to approximately $168.50 from about $169.05, reflecting modestly softer long term revenue growth expectations that are only partially offset by a marginally improved profit margin outlook and a slightly lower assumed future valuation multiple. What's in the News Pantene launched the Abundant & Strong Collection, a three step system clinically shown to reduce hair loss by up to 85% by targeting scalp oxidative stress with a Pro Vitamin Complex plus Niacinamide technology.Narratiefupdate • Dec 02
PG: Share Repurchase And New Collections Will Drive Continued Momentum
Procter & Gamble's analyst price target remains unchanged at $169.05 as analysts maintain stable estimates based on consistent fair value metrics and minimal adjustments to key financial assumptions. What's in the News Pantene launches the Abundant & Strong Collection, a new three-step system designed to reduce hair loss by up to 85% and promote stronger, denser hair using antioxidant technology.Narratiefupdate • Nov 18
PG: Share Buybacks And New Guidance Will Support Steady Uptrend
Analysts have maintained Procter & Gamble's price target at $169.05 per share. There have been only minor adjustments to underlying valuation factors, supporting a steady outlook for the company.Narratiefupdate • Nov 03
PG: Share Buyback And Product Rollout Will Drive Long-Term Upside
Analysts have slightly raised their price target for Procter & Gamble to $169.05 from $168.64. They cite incremental improvements in revenue growth forecasts even as profit margin projections moderate.Narratiefupdate • Oct 20
Rising Consumer Confidence And Product Investment Will Expand US Markets
Analysts have slightly lowered their price target for Procter & Gamble from $170.95 to $168.64 per share. They cite modest reductions in projected revenue growth, which are partially offset by improved profit margins and valuation multiples.Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $26.2B ) van PG } dekken niet de korte termijn passiva ( $38.7B ).
Langlopende schulden: De kortetermijnactiva van PG ( $26.2B ) dekken de langetermijnschulden ( $33.5B ) niet.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 44.6% ) PG wordt als hoog beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van PG is de afgelopen 5 jaar gedaald van 68.6% naar 62.9%.
Schuldendekking: De schuld van PG wordt goed gedekt door de operationele kasstroom ( 57.3% ).
Rentedekking: De rentebetalingen op de schuld van PG worden goed gedekt door EBIT ( 48.3 x dekking).
Balans
Ontdek gezonde bedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/09 04:03 |
| Aandelenkoers aan het einde van de dag | 2026/09/09 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2026/06/30 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
The Procter & Gamble Company wordt gevolgd door 40 analisten. 22 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Christopher Graja | Argus Research Company |
| Lauren Lieberman | Barclays |
| Bethan Davies | Berenberg |